CClinicalTrials.gg
Status unknownNCT04122027LTUpdated Oct 10, 2019

A Prospective Randomized Controlled Trial on the Use of Cerebral Oximetry in Adult Chinese Patients Undergoing Liver Transplantation

An interventional study of Cerebral oximeter in Liver Failure, sponsored by The University of Hong Kong. Status unknown at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-10.

Sponsored by The University of Hong Kong · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Oct 2019), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jul 2018, registered Oct 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Liver transplantation (LT) is a life-saving procedure for patients with end-stage liver diseases. Although with continuous advancement in technology, it remains a high-risk operation. The goal of LT is not only ensure survival of the patients but also to restore them back to their pre-morbid state with a good quality of life. Neurological sequelae can have major impact on postoperative outcomes after LT and yet the reported literature is scarce. Studies from Western countries showed some evidence on the use of cerebral oximtery in cardiac surgery to prevent neurological mishaps. LT shares similar intra-operative fluctuation of the haemodynamices as in cardiac surgery, causing disturbances in regional cerebral oxygenation and theorectically cerebral oximetry should be of great value as well in LT surgery. Data from a large randomised controlled trial is lacking from the current literatures. We therefore propose a prospective randomized controlled trial on the use of this device in adult LT and see whether its use could reduce neurological mishaps.

Read the detailed description

Liver Transplant Liver transplantation (LT) is a life-saving procedure for patients with end-stage liver disease. Despite continuous advancement in technology, it remains a high-risk operation. The building-up of an oxygen debt during LT can lead to an increased risk of poor postoperative outcomes (1, 2). Furthermore, patients with acute liver failure or end-stage liver disease are prone to hepatic encephalopathy, which can lead to disturbance of auto-regulation in the brain, which may eventually cause cerebral hypoxia and ischaemia. Irresversible metabolic disturbances can impair cerebral auto-regulation, causing poor neurological outcomes after LT (3). The prevalence of encephalopathy, delirium and stroke in transplant recipients is 12-40% (3). Hypotheses for these conditions include prolonged stay in the intensive care unit (ICU) (so-called "ICU psychosis"), the use of Tacrolimus (4), rapid correction of hyponatraemia (5) and impaired cerebral auto-regulation (3), but no definite conclusion can be made most of the time. Among these hypotheses, impairment of cerebral auto-regulation has never been documented in large clinical trials for Chinese patients in LT.

Cerebral oximetry (Near infra-red spectroscopy, NIRS) There is no "gold standard" for measuring cerebral auto-regulation. Monitoring of the brain oxygenation, such as direct tissue O2 tension and jugular bulb O2 saturation, has been used as a surrogate of auto-regulation but it is invasive. Transcranial laser Doppler (TCD) of the middle cerebral artery has been validated in healthy volunteers as well as real patients as a good measurement of cerebral blood flow (6, 7). Similarly, near-infrared spectroscopy (NIRS), a non-invasive and continuous method, can also monitor the regional cerebral oxygenation (rScO2) and is increasingly used in cardiac surgery. A previous report has validated the use of NIRS when compared to TCD, as the latter requires a trained technician to monitor and supervise. NIRS provides a timely, real-time, inexpensive, easily measurable alternative to TCD, and thus should have a great potential for clinical usage in LT. Similar to other non-invasive oximetry (e.g. pulse oximetry), measurement can be done through adhesive tapes over bilateral forehead and connected to the machine (INVOS™ 5100C Cerebral/Somatic Oximeter by Covidien). This system is the ONLY cerebral/somatic oximetry system with FDA cleared improved outcome claims (8). Plachky et al. showed that 50% of patients demonstrated a decline in cerebral oxygen saturation when clamping of the vessles during LT and it had positive correlation with the postoperative cerebral disrubances (9). Nonetheless, the clinical application for patients undergoing LT is scarce and its application is novel. The use of this technology may potenitally be limited by the presence of high levels of bilirubin acting as a chromophore interferring with its data acquistion. However, in a pilot study of 9 patients who underwent LT investigators using this technology were able to demonstrate that 3 out of 9 patients had either transient or persistent impaired auto regulation throughout the operation. This in turn was associated with higher Model of End-Stage Disease Score (MELD) >15 (p=0.015), more postoperative seizures and stroke (P\<0.0001) (3). A recent systematic review (10) of 901 Caucasians from 24 publications showing a decrease in NIRS (>15% relative to baseline) could have impaired postoperative cognitive function (28 versus 26; MMSE) and reduced LOS (14 versus 23 days) in open surgery. In the field of LT, impaired cerebral autoregulation (25%), cerebral deoxygenation in the anhepatic phase (36%) and cerebral hyperoxygenation with reperfusion of the grafted liver (14%) were identified by NIRS and could lead to adverse neurological outcome such as seizures, transient hemiparesis and stroke. Nonetheless, no large prospective randomized trial and no Chinese cohort were included.

References

  1. Shoemaker WC, Appel PL, Kram HB. Role of oxygen debt in the development of organ failure sepsis, and death in high-risk surgical patients. Chest. 1992;102(1):208-15.
  2. Shoemaker WC, Appel PL, Kram HB. Hemodynamic and oxygen transport responses in survivors and nonsurvivors of high-risk surgery. Critical care medicine. 1993;21(7):977-90.
  3. Lescot T, Karvellas CJ, Chaudhury P, Tchervenkov J, Paraskevas S, Barkun J, et al. Postoperative delirium in the intensive care unit predicts worse outcomes in liver transplant recipients. Can J Gastroenterol. 2013;27(4):207-12.
  4. DiMartini AF, Trzepacz PT, Pajer KA, Faett D, Fung J. Neuropsychiatric side effects of FK506 vs. cyclosporine A. First-week postoperative findings. Psychosomatics. 1997;38(6):565-9.
  5. Lee J, Kim DK, Lee JW, Oh KH, Oh YK, Na KY, et al. Rapid Correction Rate of Hyponatremia as an Independent Risk Factor for Neurological Complication Following Liver Transplantation. Tohoku J Exp Med. 2013;229(2):97-105.
  6. Lang EW, Mehdorn HM, Dorsch NW, Czosnyka M. Continuous monitoring of cerebrovascular autoregulation: a validation study. Journal of neurology, neurosurgery, and psychiatry. 2002;72(5):583-6.
  7. Ono M, Zheng Y, Joshi B, Sigl JC, Hogue CW. Validation of a stand-alone near-infrared spectroscopy system for monitoring cerebral autoregulation during cardiac surgery. Anesthesia and analgesia. 2013;116(1):198-204.
  8. Murkin JM, Adams SJ, Novick RJ, Quantz M, Bainbridge D, Iglesias I, et al. Monitoring brain oxygen saturation during coronary bypass surgery: a randomized, prospective study. Anesthesia and analgesia. 2007;104(1):51-8.
  9. Plachky J, Hofer S, Volkmann M, Martin E, Bardenheuer HJ, Weigand MA. Regional cerebral oxygen saturation is a sensitive marker of cerebral hypoperfusion during orthotopic liver transplantation. Anesth Analg. 2004;99(2):344-9.
  10. Sorensen H, Grocott HP, Secher NH. Near infrared spectroscopy for frontal lobe oxygenation during non-vascular abdominal surgery. Clin Physiol Funct Imaging. 2016;36(6):427-35.
02

Conditions studied

  • Liver Failure

Browse trials for

03

In context

Liver Failure

445 studies on the registry are indexed under Liver Failure; 69 are open to participants now.

This study's planned enrollment of 158 is above the median of 43 across 276 interventional studies indexed under Liver Failure.

Browse Liver Failure studies →

Lead sponsor

The University of Hong Kong is the lead sponsor of 1,262 studies on the registry; 340 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Able to get informed consent by patient
  • Patients undergo DDLT or LDLT at Department of Surgery, Liver Transplant Centre, The University of Hong Kong, Queen Mary Hospital
  • Ethnicity is Chinese

Exclusion criteria

Exclusion Criteria:

  • Refusal of consent by patient
  • Pre-existing neurological damage, history of seizures and on antidepressants
  • Skin conditions over forehead that precludes the application of sensors of equipment
  • Ethnicity is not Chinese
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
158 participants (estimated)

Study arms

  • Active comparator
    Control

    Patients undergoing liver transplantation without regional cerebral oxygenation monitoring using a cerebral oximeter.

    Other: Cerebral oximeter

  • Active comparator
    Intervention

    Patients undergoing liver transplantation with regional cerebral oxygenation monitoring using a cerebral oximeter.

    Other: Cerebral oximeter

Interventions

  • OtherCerebral oximeter

    Near infra-red spectroscopy, NIRS

06

What researchers measure

Primary outcomes

  1. Duration of confusion as assessed by the Confusion Assessment method

    To assess patients experience of development of delirium

    Time frame: 48 hours after liver transplant

Secondary outcomes

  1. The time taken for MOCA to return to baseline

    To assess the time patients required to return health conditions within 10 days after surgery

    Time frame: 10 days after liver transplant

  2. Other complications unrelated to neurological deficit according to Clavien-Dino Classification.

    To monitor any other complications developed by patients after liver transplant

    Time frame: 2 years

07

Study locations

2 of 2 sites recruiting
  • Queen Mary Hospital
    Hong Kong, China
    Recruiting
  • Queen mary Hospital
    Hong Kong, Hong Kong
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04122027
Lead sponsor
The University of Hong Kong
Responsible party
Dr. Kenneth Siu-Ho Chok (Associate Professor, The University of Hong Kong) — Principal investigator
First posted
Oct 10, 2019
Start date
Jul 30, 2018
Primary completion
May 31, 2020 (estimated)
Completion
May 31, 2020 (estimated)
Last update
Oct 10, 2019

Study contacts

Kenneth Chok, MBBS, MS, FRCS, FCSHK, FHKAM
Contact
chok6275@hku.hk
22553025 ext. 085222554848

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion